Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010, Article ID 539519, 9 pages
Review Article

Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?

1School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia
2National Centre for Asbestos Related Diseases, Perth, WA 6009, Australia
3School of Veterinary and Biomedical Sciences, Murdoch University, WA 6150, Australia

Received 2 July 2010; Accepted 25 August 2010

Academic Editor: Dennis Klinman

Copyright © 2010 Alison M. McDonnell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that are critical for the generation of effective cytotoxic T lymphocyte (CTL) responses; however, their function and phenotype are often defective or altered in tumor-bearing hosts, which may limit their capacity to mount an effective tumor-specific CTL response. In particular, the manner in which exogenous tumor antigens are acquired, processed, and cross-presented to CD8 T cells by DCs in tumor-bearing hosts is not well understood, but may have a profound effect on antitumor immunity. In this paper, we have examined the role of DCs in the cross-presentation of tumor antigen in terms of their subset, function, migration, and location with the intention of examining the early processes that contribute to the development of an ineffective anti-tumor immune response.